LPA receptor antagonist

Details LPA receptor antagonist LPA receptor antagonist

2003-05-28

2010-10-26

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S266200, C544S279000, C544S284000

Reexamination Certificate

active

07820682

ABSTRACT:
A compound of the general formula (I) or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).

REFERENCES:
patent: 4663473 (1987-05-01), Geigel et al.
patent: 2007/0149595 (2007-06-01), Tanaka et al.
patent: 2528846 (1976-01-01), None
patent: 341081 (1989-08-01), None
patent: 390215 (1990-10-01), None
patent: 573271 (1993-12-01), None
patent: 56/90067 (1981-07-01), None
patent: 62-164661 (1987-07-01), None
patent: 1-299283 (1989-12-01), None
patent: 10/287634 (1998-10-01), None
patent: 10-287651 (1998-10-01), None
patent: 11/158144 (1999-06-01), None
patent: 2001-226362 (2001-08-01), None
patent: 2002-293764 (2002-10-01), None
patent: WO 93/12095 (1993-06-01), None
patent: WO 95/12572 (1995-05-01), None
patent: WO 99/08501 (1999-02-01), None
patent: WO 01/00206 (2001-01-01), None
patent: WO 02/00646 (2002-01-01), None
patent: WO 02/29001 (2002-04-01), None
patent: WO 02/062389 (2002-08-01), None
patent: WO 02/062798 (2002-08-01), None
patent: 2004/002530 (2004-01-01), None
patent: 2004/031118 (2004-04-01), None
Aldrich Chemical Company; Technical Bulletin AL-110, Oxalyl Chloride; Apr. 1996; p. 2.
Roger Salmon; Oxalyl Chloride; Apr. 15, 2001; Encyclopedia of Reagents for Organic Synthesis; p. 6.
Wouter I. Iwema Bakker et. al.; Lithium Diisopropylamide; Oct. 15, 2004; Encyclopedia of Reagents for Organic Synthesis; p. 2, 15-16.
M.S. Kharasch, et. al.; Carboxylation II: The reaction of Oxalyl Chloride with Unsaturated Hydrocarbons; Journal of American Chemical Society; 64, 333 (1942).
Luca Banfi et. al.; Sodium Borohydride; Apr. 15, 2001; Encyclopedia of Reagents for Organic Synthesis; p. 1, 2, and 7.
Chawla et. al.; Current Research & Information on Pharmaceutical Science, 2004, 5(1), p. 9, col. 2, para.1.
Schiaffino et. al., J.Behav.Med., 1995, 18(6), p. 531-548.
http://www.msakc.org/Articles/MSPain.htm.
Newman et. al.; Drug Discovery Today, 2003, 8(19), p. 899, col. 2, Box 1.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
International Search Report for PCT/JP04/019456 Apr. 12, 2005.
Contos et al., Lysophasphatidic Acid Receptors, Mol Pharmacol, vol. 58: 1188-1196, 2000.
U.S. Office Action dated Oct. 1, 2009 (U.S. Appl. No. 12/112,563).
Banker, et al., “Modern Pharmaceuticals,” 3rd Ed., pp. 596 (1996).
Wolff, et al., “Burger's Medicinal Chemistry and Drug Discovery,” 5th Ed. Pat 1, pp. 975-977 (1995).
Kubinyi, H.; 3D Qsar in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, pp. 800.
International Search Report for PCT/JP03/06680 dated Aug. 19, 2003.

Affiliated with

Also associated with

Rating

LPA receptor antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LPA receptor antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LPA receptor antagonist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4206792